A NEW exploratory study highlights the value of optical coherence tomography (OCT) in assessing long-term treatment effects of risankizumab in patients with moderate-to-severe psoriasis, revealing improvements beyond what is visible on clinical examination alone. Optical Coherence Tomography in Psoriasis MonitoringThis prospective, single-centre sub-analysis included 22 patients with moderate-to-severe psoriasis treated with risankizumab for up to 52 weeks. At week 52, 86.7% of patients achieved PASI 75, 73.3% achieved PASI 90, and 40.0% achieved complete skin clearance (PASI 100). Assessing Long-Term Psoriasis Outcomes with OCTThe authors conclude that risankizumab provides sustained clinical and microstructural benefits in psoriasis, supporting the importance of long-term therapy. Evaluating Risankizumab’s Long-Term Effects in Psoriasis Using Optical Coherence Tomography.